Compare Autodesk Inc (ADSK) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs Crispr Therapeutics AG — how do they compare? Autodesk Inc trades at $207.43 (market cap $44.84B), while Crispr Therapeutics AG trades at $58.89 (market cap $5.98B). The key difference: Autodesk Inc is far larger — about 7.5× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | CRSP | |
|---|---|---|
Market Cap | $44.84B | $5.98B |
Sector | Technology | Health |
52-Week High | $326.79 | $76.78 |
52-Week Low | $187.72 | $44.34 |
Enterprise Value | $44.64B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.
Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.
CRISPR Therapeutics (CRSP) trades at $60.77, up 1.15% with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company maintains strong cash reserves despite negative profitability metrics, with recent FDA approval for Casgevy pediatric use expanding its commercial potential. Technical indicators show the stock trading near pivot point resistance at $61 with RSI levels suggesting potential overbought conditions.
While CRSP shows promising growth potential with its pioneering gene-editing technology and recent regulatory wins, investors face significant risks from persistent negative margins and cash burn. The stock offers 19.6% upside to the consensus price target of $72.67, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
